Danlaw Technologies India Ltd
532329Danlaw Technologies India Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is already 14 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (14 weeks in) while the P/E sits at the 49th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +70.9% year on year, and 86% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Danlaw Technologies India Ltd trades at ₹1,626, in a confirmed uptrend and 14 weeks into that stage. That is +54.7% against its own 200-day average. It sits at 83% of a 52-week range of ₹746 to ₹1,805. On relative strength it has no relative-strength read yet.
Today the stock is in a confirmed uptrend — week 14 of stage 2, confirmed. At ₹1,626 it trades +54.7% versus its 200-day average and sits at 83% of its 52-week range (₹746–₹1,805).
Against the market, two honest reads. Cumulative: over the last 4 months the stock moved +118% while the NIFTY 500 moved +1% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Danlaw Technologies India Ltd trades at 31.1× P/E, mid-range by its own standards (49th percentile). Its long-run median P/E is 32.0×, measured across 10.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 31.1× is mid-range by its own standards (49th percentile), against a long-run median of 32.0× measured over 10.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Danlaw Technologies India Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −14.2% at the trough to +34.5%, a 4-quarter improving streak, ROCE lifting at 28.0%. The read is built from 12 quarters across 4 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +20.2% | +16.2% | +56.4% | +37.3% |
| Profit | +21.1% | +48.7% | — | +27.7% |
| EPS | +21.5% | +46.9% | — | +24.9% |
4-Factor Sector Score
60.0/100 — rank 14 of 64 in IT - Software · 67% evidence confidence
Danlaw Technologies India Ltd scores 60.0 out of 100 against the 64 companies it is compared with in IT - Software, ranking 14. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 21.9 + 15.5 + 10.2 + 12.4 = 60. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Danlaw Technologies India Ltd reported ₹73.7 Cr of revenue in the Jun 26 quarter, +34.6% year on year. That is the 9th straight quarter of year-on-year growth. Over 10 years it has compounded at 37.3% a year. The last full year, FY26, came in at ₹262 Cr. The last four reported quarters add to ₹281 Cr.
FY26 revenue came in at ₹262 Cr (+20.2% on the year), capping 10 years at 37.3% compound. The latest quarter (Jun 26) printed ₹73.7 Cr, +34.6% year on year — the 9th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +23.9% growth against the decade's 37.3% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +24.1% over the last 4 quarters against +15.1%/yr over the last 8 — accelerating; TTM profit +34.5% vs +7.5%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Danlaw Technologies India Ltd's operating margin is 13.4% in the Jun 26 quarter, +0.8 percentage points against the same quarter a year ago. Across 16 fiscal years the operating margin has ranged −21.0% to 18.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 13.4%, +0.8 pp against the same quarter a year ago. Across 16 fiscal years the operating margin has ranged −21.0%–18.0%.
Why the margin moved: operating margin went +0.8 pp year on year while gross margin went −3.8 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Danlaw Technologies India Ltd earned ₹5.9 Cr of net profit in the Jun 26 quarter, +70.9% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹23.0 Cr. The 10-year compound rate is 27.7%. That is 8.0% of the quarter's revenue. The same quarter a year earlier earned ₹3.5 Cr.
Jun 26 profit was ₹5.9 Cr, +70.9% year on year — the 4th consecutive quarter of growth. On the full year, FY26 printed ₹23.0 Cr (+21.1%), and the 10-year compound rate is 27.7%.
Why profit moved: revenue contributed +34.6% and the margin +0.8 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +35.1% vs revenue +23.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 86% of Danlaw Technologies India Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹21.0 Cr of operating cash against ₹23.0 Cr of profit. After ₹12.0 Cr of capital spending, ₹9.0 Cr was left as free cash.
FY26: operating cash of ₹21.0 Cr against reported profit of ₹23.0 Cr, leaving free cash of ₹9.0 Cr after ₹12.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 86% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 86%: the cash cycle stretched 111 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 1.9× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Danlaw Technologies India Ltd's cash conversion cycle runs 110 days in FY26, up from −1 days in FY21. Capital spending ran ₹30.0 Cr over the last 3 years. At FY26 sales of ₹262 Cr each day of that cycle holds about ₹0.7 Cr, so roughly ₹79.0 Cr sits inside the business at any moment.
FY26: debtors at 78 days, inventory at 104 days — roughly 3.4 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 110 days, looser than FY21's −1.
The full loop: cash goes out to suppliers and production on day 0; stock waits 104 days to sell; customers pay about 78 days after that; and suppliers themselves are paid at 72 days — netting out to the 110-day cycle.
In money terms: at FY26 sales of ₹262 Cr, each day of the cycle holds about ₹0.7 Cr — so the 110-day loop keeps roughly ₹79.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹30.0 Cr over the last 3 fiscal years against ₹16.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹8.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Danlaw Technologies India Ltd earns a ROCE of 28% in FY26. That is up from a trough of −17% in FY20. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 8.8% net margin on 1.43× asset turns.
FY26 ROCE is 28%, recovered from a FY20 trough of −17% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 8.8% net margin × 1.43× asset turns × 1.83× balance-sheet leverage ≈ 23.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Danlaw Technologies India Ltd carries ₹30.0 Cr of borrowings against ₹100 Cr of equity in FY26, a debt-to-equity of 0.30. Operating profit covers the interest bill 20×. Over 5 years borrowings went from ₹1.0 Cr to ₹30.0 Cr. Capital spending ran ₹30.0 Cr across the last 3 of those years.
FY26: borrowings of ₹30.0 Cr against equity of ₹100 Cr — a debt-to-equity of 0.30. Operating profit covers the interest bill 20×. Over 5 years borrowings went from ₹1.0 Cr to ₹30.0 Cr while capital spending ran ₹30.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Danlaw Technologies India Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved +0.0 points over the same window, to 0.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +0.0 points over 8 quarters to 61.9%; Foreign institutions: +0.0 points over 8 quarters to 0.0%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Danlaw Technologies India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Coforge LtdCOFORGE | 76.3/100Favorable setup100% evidence | LEADER | 30.0/35 Revenue 35.7% · PAT 66.5% · OPM change 3 pp 100% evidence | 15.6/25 ROCE 23.5% · OPM 19% 100% evidence | 12.3/20 P/E 42.5× · PEG 0.57 100% evidence | 18.4/20 RS sector 14.1% · RS bench 19.8% · 1Y 4.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30 + 15.6 + 12.3 + 18.4 = 76.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Silver Touch Technologies LtdSILVERTUC | 69.0/100Favorable setup93% evidence | FADING | 30.2/35 Revenue 21.1% · PAT 86.4% · OPM change 8 pp 100% evidence | 17.4/25 ROCE 29.8% · OPM 22% 100% evidence | 10.3/20 P/E 44.5× · PEG 1.11 65% evidence | 11.1/20 RS sector 2% · RS bench 8.4% · 1Y 101.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 30.2 + 17.4 + 10.3 + 11.1 = 69 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3ASM Technologies Ltd526433 | 68.5/100Favorable setup69% evidence | BREAKING OUT | 28.0/35 Revenue 67.8% · PAT 89.5% · OPM change 2 pp 95% evidence | 16.1/25 ROCE 27% · OPM 23% 76% evidence | 8.7/20 P/E 137× · PEG — 15% evidence | 15.7/20 RS sector 5.7% · RS bench 93.3% · 1Y 56.7%10 of 10 weeks ahead 70% evidence |
| Exact sum: 28 + 16.1 + 8.7 + 15.7 = 68.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Sahana Systems LtdSAHANA | 68.1/100Favorable setup70% evidence | BREAKING OUT | 21.6/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 19.9/25 ROCE 39.8% · OPM 29% 95% evidence | 13.4/20 P/E 13.3× · PEG — 50% evidence | 13.2/20 RS sector -9.5% · RS bench 9.3% · 1Y -28.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 19.9 + 13.4 + 13.2 = 68.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Softtech Engineers LtdSOFTTECH | 65.3/100Favorable setup80% evidence | TURNING | 25.3/35 Revenue 35.8% · PAT 100% · OPM change -0.1 pp 95% evidence | 12.2/25 ROCE 6.2% · OPM 27.2% 95% evidence | 8.6/20 P/E 144× · PEG — 15% evidence | 19.2/20 RS sector 39.8% · RS bench 47.2% · 1Y 35.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 25.3 + 12.2 + 8.6 + 19.2 = 65.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6NINtec Systems LtdNINSYS | 65.1/100Favorable setup80% evidence | FADING | 20.1/35 Revenue 21.6% · PAT 18.8% · OPM change 4.2 pp 95% evidence | 21.9/25 ROCE 54% · OPM 25.9% 95% evidence | 9.3/20 P/E 39.2× · PEG — 15% evidence | 13.8/20 RS sector 29.7% · RS bench 36.3% · 1Y 58.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 21.9 + 9.3 + 13.8 = 65.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7String Metaverse Ltd534535 | 63.6/100Mixed-positive evidence82% evidence | TURNING | 27.3/35 Revenue 100% · PAT 100% · OPM change 0 pp 95% evidence | 15.7/25 ROCE 41.6% · OPM 11% 76% evidence | 14.7/20 P/E 8.1× · PEG — 50% evidence | 5.9/20 RS sector -47.1% · RS bench -35.2% · 1Y -67.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 27.3 + 15.7 + 14.7 + 5.9 = 63.6 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -47.1% and the one-year return is -67.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 8TAC Infosec LtdTAC | 63.5/100Mixed-positive evidence66% evidence | BREAKING OUT | 25.7/35 Revenue 76.4% · PAT 59.4% · OPM change 1.6 pp 71% evidence | 20.9/25 ROCE 38.1% · OPM 48.2% 95% evidence | 9.3/20 P/E 37.5× · PEG — 15% evidence | 7.6/20 RS sector -13.2% · RS bench -10.8% · 1Y -11.8%5 of 10 weeks ahead 70% evidence |
| Exact sum: 25.7 + 20.9 + 9.3 + 7.6 = 63.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Tech Mahindra LtdTECHM | 63.3/100Mixed-positive evidence94% evidence | BREAKING OUT | 21.1/35 Revenue 10.9% · PAT 14.3% · OPM change 3 pp 100% evidence | 16.3/25 ROCE 23.1% · OPM 17% 100% evidence | 10.6/20 P/E 28.3× · PEG 0.76 100% evidence | 15.3/20 RS sector 14.8% · RS bench 3.8% · 1Y 0.8%9 of 11 weeks ahead 70% evidence |
| Exact sum: 21.1 + 16.3 + 10.6 + 15.3 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Cigniti Technologies LtdCIGNITITEC | 63.2/100Mixed-positive evidence73% evidence | 23.4/35 Revenue 14% · PAT 96.1% · OPM change 2 pp 56% evidence | 16.2/25 ROCE 34.1% · OPM 18% 75% evidence | 16.1/20 P/E 11.4× · PEG 0.61 100% evidence | 7.5/20 RS sector -10.2% · RS bench -15% · 1Y -24.6%0 of 12 weeks ahead to 2026-05-17 70% evidence | |
| Exact sum: 23.4 + 16.2 + 16.1 + 7.5 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Sasken Technologies LtdSASKEN | 61.7/100Mixed-positive evidence100% evidence | ASLEEP | 30.8/35 Revenue 67.8% · PAT 67.4% · OPM change 4 pp 100% evidence | 8.2/25 ROCE 9.9% · OPM 9% 100% evidence | 10.4/20 P/E 35.4× · PEG 0.68 100% evidence | 12.3/20 RS sector 6.4% · RS bench 12.2% · 1Y 15.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 8.2 + 10.4 + 12.3 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Datamatics Global Services LtdDATAMATICS | 61.2/100Mixed-positive evidence94% evidence | ASLEEP | 21.1/35 Revenue 13.1% · PAT 1.9% · OPM change 4 pp 100% evidence | 16.0/25 ROCE 20.4% · OPM 20% 100% evidence | 10.6/20 P/E 17.8× · PEG 0.69 100% evidence | 13.5/20 RS sector 9.6% · RS bench -2.2% · 1Y -16.6%4 of 10 weeks ahead 70% evidence |
| Exact sum: 21.1 + 16 + 10.6 + 13.5 = 61.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13IZMO LtdIZMO | 61.0/100Mixed-positive evidence81% evidence | ASLEEP | 24.3/35 Revenue 24.7% · PAT 10.2% · OPM change 8 pp 95% evidence | 14.3/25 ROCE 12.6% · OPM 25% 95% evidence | 6.6/20 P/E 26× · PEG — 50% evidence | 15.8/20 RS sector 29% · RS bench 11.2% · 1Y 12.8%7 of 10 weeks ahead 70% evidence |
| Exact sum: 24.3 + 14.3 + 6.6 + 15.8 = 61 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Danlaw Technologies India Ltdthis page532329 | 60.0/100Mixed-positive evidence67% evidence | BREAKING OUT | 21.9/35 Revenue 24.1% · PAT 34.5% · OPM change 0.8 pp 95% evidence | 15.5/25 ROCE 27.6% · OPM 13.4% 76% evidence | 10.2/20 P/E 31.1× · PEG — 50% evidence | 12.4/20 RS sector — · RS bench 85.1% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 21.9 + 15.5 + 10.2 + 12.4 = 60 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Expleo Solutions LtdEXPLEOSOL | 59.6/100Mixed-positive evidence81% evidence | TURNING | 21.0/35 Revenue 10.4% · PAT 39.4% · OPM change 4 pp 95% evidence | 15.8/25 ROCE 24.2% · OPM 15% 95% evidence | 13.6/20 P/E 9.3× · PEG — 50% evidence | 9.2/20 RS sector -13.3% · RS bench 1% · 1Y -10.8%2 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 15.8 + 13.6 + 9.2 = 59.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Infosys LtdINFY | 58.7/100Mixed-positive evidence82% evidence | TURNING | 18.2/35 Revenue 11.2% · PAT 11.1% · OPM change 0 pp 95% evidence | 20.1/25 ROCE 40% · OPM 24% 76% evidence | 14.1/20 P/E 13.7× · PEG — 50% evidence | 6.3/20 RS sector -23.9% · RS bench -19.5% · 1Y -31.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 20.1 + 14.1 + 6.3 = 58.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17InfoBeans Technologies LtdINFOBEAN | 58.5/100Mixed-positive evidence87% evidence | ASLEEP | 26.5/35 Revenue 35.5% · PAT 60.4% · OPM change 0 pp 95% evidence | 16.9/25 ROCE 29.2% · OPM 21% 95% evidence | 9.7/20 P/E 17.3× · PEG — 50% evidence | 5.4/20 RS sector -13.6% · RS bench -8.2% · 1Y 7.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 26.5 + 16.9 + 9.7 + 5.4 = 58.5 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -13.6% and the one-year return is 7.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 18R Systems International LtdRSYSTEMS | 57.8/100Mixed-positive evidence100% evidence | BASING | 19.0/35 Revenue 24.1% · PAT -1% · OPM change 3 pp 100% evidence | 16.6/25 ROCE 19.5% · OPM 18% 100% evidence | 17.6/20 P/E 13.6× · PEG 0.26 100% evidence | 4.6/20 RS sector -26.1% · RS bench -22.1% · 1Y -46.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 16.6 + 17.6 + 4.6 = 57.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19BLS E-Services LtdBLSE | 57.2/100Mixed-positive evidence75% evidence | LEADER | 18.2/35 Revenue 71.2% · PAT 9.4% · OPM change 0 pp 95% evidence | 10.3/25 ROCE 16.4% · OPM 7% 76% evidence | 9.0/20 P/E 49.5× · PEG — 15% evidence | 19.7/20 RS sector 43.6% · RS bench 50.7% · 1Y 66.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 10.3 + 9 + 19.7 = 57.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Subex LtdSUBEXLTD | 56.8/100Mixed-positive evidence65% evidence | BREAKING OUT | 24.5/35 Revenue 2.8% · PAT 100% · OPM change 13 pp 95% evidence | 10.4/25 ROCE 12.8% · OPM 19% 95% evidence | 9.5/20 P/E 35× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 72.5% · 1Y —10 of 10 weeks ahead 25% evidence |
| Exact sum: 24.5 + 10.4 + 9.5 + 12.4 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Ksolves India LtdKSOLVES | 56.7/100Mixed-positive evidence87% evidence | ASLEEP | 17.8/35 Revenue 16% · PAT 16.7% · OPM change 3.9 pp 95% evidence | 20.7/25 ROCE 131% · OPM 30.3% 95% evidence | 13.7/20 P/E 16.1× · PEG — 50% evidence | 4.5/20 RS sector -17.4% · RS bench -12.6% · 1Y -22.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 20.7 + 13.7 + 4.5 = 56.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22LTM LtdLTM | 54.9/100Mixed-positive evidence100% evidence | BREAKING OUT | 17.2/35 Revenue 13.9% · PAT 10% · OPM change 1 pp 100% evidence | 17.9/25 ROCE 29.6% · OPM 18% 100% evidence | 10.7/20 P/E 22.6× · PEG 1.18 100% evidence | 9.1/20 RS sector -15.9% · RS bench -11.2% · 1Y -19.8%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 17.9 + 10.7 + 9.1 = 54.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Saksoft LtdSAKSOFT | 54.7/100Mixed-positive evidence100% evidence | FADING | 18.0/35 Revenue 8.2% · PAT 13% · OPM change 0 pp 100% evidence | 15.6/25 ROCE 25.5% · OPM 18% 100% evidence | 13.5/20 P/E 14× · PEG 0.6 100% evidence | 7.6/20 RS sector -17.5% · RS bench -13.2% · 1Y -32.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 15.6 + 13.5 + 7.6 = 54.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Xchanging Solutions LtdXCHANGING | 54.1/100Mixed-positive evidence81% evidence | BASING | 18.7/35 Revenue 8.4% · PAT 13.2% · OPM change 1 pp 95% evidence | 15.6/25 ROCE 18% · OPM 34% 95% evidence | 13.9/20 P/E 11.4× · PEG — 50% evidence | 5.9/20 RS sector -24.4% · RS bench -10.7% · 1Y -29.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 18.7 + 15.6 + 13.9 + 5.9 = 54.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Blue Cloud Softech Solutions LtdBLUECLOUDS | 53.0/100Mixed-positive evidence74% evidence | 22.0/35 Revenue 41.1% · PAT 36.2% · OPM change 10 pp 95% evidence | 12.5/25 ROCE 14.2% · OPM 20% 95% evidence | 9.6/20 P/E 27.9× · PEG — 15% evidence | 8.9/20 RS sector -3.8% · RS bench -9.6% · 1Y -36.8%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 22 + 12.5 + 9.6 + 8.9 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26TechNVision Ventures LtdTECHNVISN | 52.6/100Mixed-positive evidence74% evidence | ASLEEP | 26.0/35 Revenue 23.4% · PAT 100% · OPM change 2.9 pp 95% evidence | 5.7/25 ROCE 12.9% · OPM 5.2% 95% evidence | 8.5/20 P/E 910× · PEG — 15% evidence | 12.4/20 RS sector 32.1% · RS bench -21.9% · 1Y -25.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 26 + 5.7 + 8.5 + 12.4 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Seshaasai Technologies LtdSTYL | 52.4/100Mixed-positive evidence73% evidence | BREAKING OUT | 12.6/35 Revenue 6.7% · PAT 20.6% · OPM change 0 pp 100% evidence | 17.1/25 ROCE 27.7% · OPM 23% 100% evidence | 12.7/20 P/E 22.1× · PEG 0.81 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y -15.4%10 of 10 weeks ahead 0% evidence |
| Exact sum: 12.6 + 17.1 + 12.7 + 10 = 52.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Tanla Platforms LtdTANLA | 52.3/100Mixed-positive evidence94% evidence | ASLEEP | 14.5/35 Revenue 13.2% · PAT 9.9% · OPM change 0 pp 100% evidence | 16.5/25 ROCE 26.3% · OPM 16% 100% evidence | 13.2/20 P/E 12.2× · PEG 1.21 100% evidence | 8.1/20 RS sector -12% · RS bench -7.3% · 1Y -29.7%5 of 10 weeks ahead 70% evidence |
| Exact sum: 14.5 + 16.5 + 13.2 + 8.1 = 52.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 29AvenuesAI LtdCCAVENUE | 51.4/100Mixed-positive evidence93% evidence | LEADER | 21.0/35 Revenue 100% · PAT 43.8% · OPM change -2.3 pp 100% evidence | 5.2/25 ROCE 7.7% · OPM 3.7% 100% evidence | 14.8/20 P/E 18.9× · PEG 0.37 65% evidence | 10.4/20 RS sector -4.8% · RS bench 0.5% · 1Y 0.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 5.2 + 14.8 + 10.4 = 51.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Tata Consultancy Services LtdTCS | 50.9/100Mixed-positive evidence100% evidence | TURNING | 10.2/35 Revenue 7.7% · PAT 1.1% · OPM change -1 pp 100% evidence | 22.5/25 ROCE 63% · OPM 26% 100% evidence | 11.9/20 P/E 14.2× · PEG 1.85 100% evidence | 6.3/20 RS sector -23.6% · RS bench -19.2% · 1Y -32.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.2 + 22.5 + 11.9 + 6.3 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31RNIT AI Solutions LtdAUTOPALIND | 50.5/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.9/35 Revenue 56.7% · PAT 71.3% · OPM change -0.6 pp 95% evidence | 14.7/25 ROCE 20.2% · OPM 35.3% 76% evidence | 8.9/20 P/E 63.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 12 weeks ahead 0% evidence |
| Exact sum: 16.9 + 14.7 + 8.9 + 10 = 50.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Birlasoft LtdBSOFT | 50.4/100Mixed-positive evidence100% evidence | ASLEEP | 19.8/35 Revenue 1.4% · PAT 21.1% · OPM change 4 pp 100% evidence | 13.0/25 ROCE 21.2% · OPM 16% 100% evidence | 14.6/20 P/E 13.2× · PEG 0.62 100% evidence | 3.0/20 RS sector -25.2% · RS bench -20.6% · 1Y -25%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 13 + 14.6 + 3 = 50.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33Capillary Technologies India LtdCAPILLARY | 50.4/100Mixed-positive evidence63% evidence | ASLEEP | 27.5/35 Revenue 27.8% · PAT 135.8% · OPM change 5.8 pp 100% evidence | 4.1/25 ROCE 3.4% · OPM 15.7% 100% evidence | 8.8/20 P/E 75.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 27.5 + 4.1 + 8.8 + 10 = 50.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34HCL Technologies LtdHCLTECH | 49.7/100Mixed-negative evidence82% evidence | BREAKING OUT | 12.3/35 Revenue 12.6% · PAT 2.6% · OPM change 0 pp 95% evidence | 19.0/25 ROCE 30.4% · OPM 20% 76% evidence | 8.9/20 P/E 18.7× · PEG — 50% evidence | 9.5/20 RS sector -14.2% · RS bench -9.2% · 1Y -14.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 19 + 8.9 + 9.5 = 49.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Hexaware Technologies LtdHEXT | 49.4/100Mixed-negative evidence94% evidence | TURNING | 14.3/35 Revenue 13% · PAT 1.2% · OPM change 4 pp 100% evidence | 17.8/25 ROCE 30.1% · OPM 16% 100% evidence | 10.6/20 P/E 22.6× · PEG 0.81 100% evidence | 6.7/20 RS sector -21.4% · RS bench -9.2% · 1Y -30.8%7 of 10 weeks ahead 70% evidence |
| Exact sum: 14.3 + 17.8 + 10.6 + 6.7 = 49.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Mphasis LtdMPHASIS | 49.1/100Mixed-negative evidence94% evidence | FADING | 15.1/35 Revenue 13.7% · PAT 9.9% · OPM change -1 pp 100% evidence | 17.3/25 ROCE 22.1% · OPM 18% 100% evidence | 5.9/20 P/E 22.7× · PEG 2.19 100% evidence | 10.8/20 RS sector 0% · RS bench -6.2% · 1Y -20.8%3 of 10 weeks ahead 70% evidence |
| Exact sum: 15.1 + 17.3 + 5.9 + 10.8 = 49.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 37Zensar Technologies LtdZENSARTECH | 48.8/100Mixed-negative evidence100% evidence | BASING | 15.7/35 Revenue 8% · PAT 15.3% · OPM change 0 pp 100% evidence | 13.6/25 ROCE 22.8% · OPM 15% 100% evidence | 14.2/20 P/E 12.5× · PEG 1.11 100% evidence | 5.3/20 RS sector -29.6% · RS bench -25.7% · 1Y -46.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 13.6 + 14.2 + 5.3 = 48.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 38Mastek LtdMASTEK | 47.7/100Mixed-negative evidence82% evidence | BREAKING OUT | 13.8/35 Revenue 6% · PAT 5% · OPM change 0 pp 95% evidence | 13.4/25 ROCE 17.7% · OPM 15% 76% evidence | 12.7/20 P/E 11.2× · PEG — 50% evidence | 7.8/20 RS sector -16.8% · RS bench -12.3% · 1Y -35.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 13.4 + 12.7 + 7.8 = 47.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Unicommerce eSolutions LtdUNIECOM | 46.6/100Mixed-negative evidence74% evidence | ASLEEP | 14.5/35 Revenue 38.4% · PAT 18.1% · OPM change -8.1 pp 95% evidence | 16.5/25 ROCE 21.1% · OPM 10.6% 95% evidence | 9.0/20 P/E 44× · PEG — 15% evidence | 6.6/20 RS sector -14.5% · RS bench -18.4% · 1Y -41.4%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.5 + 16.5 + 9 + 6.6 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40XT Global Infotech LtdXTGLOBAL | 46.5/100Mixed-negative evidence61% evidence | 18.5/35 Revenue 85.4% · PAT 29.4% · OPM change -6.6 pp 53% evidence | 9.4/25 ROCE 7.5% · OPM 9.5% 71% evidence | 9.1/20 P/E 40.8× · PEG — 50% evidence | 9.5/20 RS sector -1% · RS bench -12.7% · 1Y -29.4%2 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 18.5 + 9.4 + 9.1 + 9.5 = 46.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Dynacons Systems & Solutions LtdDSSL | 46.4/100Mixed-negative evidence87% evidence | ASLEEP | 16.9/35 Revenue 10.5% · PAT 16.2% · OPM change 3 pp 95% evidence | 15.4/25 ROCE 29.8% · OPM 13% 95% evidence | 8.2/20 P/E 15.2× · PEG — 50% evidence | 5.9/20 RS sector -9.9% · RS bench -4.6% · 1Y 5.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 15.4 + 8.2 + 5.9 = 46.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 42Wipro LtdWIPRO | 45.9/100Mixed-negative evidence100% evidence | BASING | 13.0/35 Revenue 6.4% · PAT -1.7% · OPM change 0 pp 100% evidence | 15.4/25 ROCE 17.8% · OPM 19% 100% evidence | 13.5/20 P/E 12.5× · PEG 1.4 100% evidence | 4.0/20 RS sector -24.7% · RS bench -20.4% · 1Y -33.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 15.4 + 13.5 + 4 = 45.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 43Excelsoft Technologies LtdEXCELSOFT | 44.6/100Mixed-negative evidence60% evidence | TURNING | 12.1/35 Revenue 26.8% · PAT 4.2% · OPM change -1.8 pp 95% evidence | 12.3/25 ROCE 13.6% · OPM 16.3% 95% evidence | 10.2/20 P/E 18× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 12.1 + 12.3 + 10.2 + 10 = 44.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 44Hypersoft Technologies Ltd539724 | 44.0/100Mixed-negative evidence67% evidence | FADING | 17.4/35 Revenue 100% · PAT 100% · OPM change 2.9 pp 71% evidence | 5.3/25 ROCE 4.8% · OPM 14% 76% evidence | 8.6/20 P/E 314× · PEG — 15% evidence | 12.7/20 RS sector 14.5% · RS bench 21% · 1Y 95.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 5.3 + 8.6 + 12.7 = 44 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4563 Moons Technologies Ltd63MOONS | 43.4/100Thin evidence · provisional58% evidence | BREAKING OUT | 20.7/35 Revenue 100% · PAT -80% · OPM change 128 pp 71% evidence | 3.4/25 ROCE -3.7% · OPM -52% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.3/20 RS sector -22.4% · RS bench 25.7% · 1Y -6%10 of 11 weeks ahead 70% evidence |
| Exact sum: 20.7 + 3.4 + 10 + 9.3 = 43.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46Sonata Software LtdSONATSOFTW | 42.0/100Mixed-negative evidence100% evidence | ASLEEP | 9.1/35 Revenue 4% · PAT 7.9% · OPM change 0 pp 100% evidence | 13.6/25 ROCE 30.7% · OPM 5% 100% evidence | 13.0/20 P/E 15.2× · PEG 0.81 100% evidence | 6.3/20 RS sector -13.2% · RS bench -8.7% · 1Y -28.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 9.1 + 13.6 + 13 + 6.3 = 42 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 47Magellanic Cloud LtdMCLOUD | 39.1/100Mixed-negative evidence81% evidence | ASLEEP | 9.7/35 Revenue 13.7% · PAT 6.7% · OPM change -7 pp 95% evidence | 14.0/25 ROCE 19.8% · OPM 28% 95% evidence | 11.9/20 P/E 13.4× · PEG — 50% evidence | 3.5/20 RS sector -54.4% · RS bench -22.2% · 1Y -67.5%5 of 11 weeks ahead 70% evidence |
| Exact sum: 9.7 + 14 + 11.9 + 3.5 = 39.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 48Innovana Thinklabs LtdINNOVANA | 38.6/100Mixed-negative evidence81% evidence | BASING | 8.8/35 Revenue 26% · PAT -39% · OPM change -32.5 pp 95% evidence | 11.4/25 ROCE 15.8% · OPM 17.6% 95% evidence | 9.0/20 P/E 20.3× · PEG — 50% evidence | 9.4/20 RS sector -0.4% · RS bench -20.2% · 1Y -43.9%0 of 10 weeks ahead 70% evidence |
| Exact sum: 8.8 + 11.4 + 9 + 9.4 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 49Kellton Tech Solutions LtdKELLTONTEC | 37.2/100Mixed-negative evidence87% evidence | BASING | 10.1/35 Revenue 9.5% · PAT 9.6% · OPM change -1 pp 95% evidence | 9.8/25 ROCE 15% · OPM 11% 95% evidence | 11.9/20 P/E 7.9× · PEG — 50% evidence | 5.4/20 RS sector -23.3% · RS bench -19% · 1Y -49.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.1 + 9.8 + 11.9 + 5.4 = 37.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 50Aurionpro Solutions LtdAURIONPRO | 35.8/100Mixed-negative evidence93% evidence | ASLEEP | 12.9/35 Revenue 14.8% · PAT 5.1% · OPM change -3 pp 100% evidence | 10.8/25 ROCE 16.3% · OPM 17% 100% evidence | 9.9/20 P/E 18.1× · PEG 1.39 65% evidence | 2.2/20 RS sector -28.2% · RS bench -24.2% · 1Y -42.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 10.8 + 9.9 + 2.2 = 35.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 51Allied Digital Services LtdADSL | 35.1/100Mixed-negative evidence74% evidence | ASLEEP | 14.3/35 Revenue 19.1% · PAT 5.6% · OPM change 0 pp 95% evidence | 6.6/25 ROCE 7.4% · OPM 9% 95% evidence | 10.7/20 P/E 14× · PEG — 15% evidence | 3.5/20 RS sector -29.8% · RS bench -26.4% · 1Y -42.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.3 + 6.6 + 10.7 + 3.5 = 35.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 52Mindteck (India) LtdMINDTECK | 32.4/100Adverse evidence87% evidence | ASLEEP | 8.0/35 Revenue -1.8% · PAT 0.3% · OPM change -1.7 pp 95% evidence | 10.6/25 ROCE 15.1% · OPM 7.8% 95% evidence | 11.8/20 P/E 15.3× · PEG — 50% evidence | 2.0/20 RS sector -26.8% · RS bench -22.7% · 1Y -27.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 8 + 10.6 + 11.8 + 2 = 32.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 53Moschip Technologies LtdMOSCHIP | 31.5/100Adverse evidence87% evidence | BASING | 7.8/35 Revenue 8.4% · PAT -33.6% · OPM change -3.9 pp 100% evidence | 7.2/25 ROCE 11% · OPM 8.2% 100% evidence | 3.7/20 P/E 128× · PEG 5.04 65% evidence | 12.8/20 RS sector 1.9% · RS bench 0.9% · 1Y -18.4%2 of 10 weeks ahead 70% evidence |
| Exact sum: 7.8 + 7.2 + 3.7 + 12.8 = 31.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 54Orient Technologies LtdORIENTTECH | 30.1/100Thin evidence · provisional54% evidence | BASING | 15.2/35 Revenue — · PAT — · OPM change -0.5 pp 19% evidence | 2.5/25 ROCE 8.4% · OPM 6.7% 95% evidence | 9.1/20 P/E 43.2× · PEG — 15% evidence | 3.3/20 RS sector -24.8% · RS bench -20.6% · 1Y -18%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 2.5 + 9.1 + 3.3 = 30.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 55Quick Heal Technologies LtdQUICKHEAL | 21.4/100Adverse evidence69% evidence | BASING | 6.3/35 Revenue -6.6% · PAT -80% · OPM change -22.1 pp 71% evidence | 1.8/25 ROCE -6% · OPM -39% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.3/20 RS sector -28.9% · RS bench -25.4% · 1Y -53.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 6.3 + 1.8 + 10 + 3.3 = 21.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 56Covance Softsol Ltd544361 | 66.9/100Thin evidence · provisional49% evidence | 25.8/35 Revenue 43.5% · PAT 100% · OPM change 19.7 pp 62% evidence | 17.8/25 ROCE 31.4% · OPM 23.1% 76% evidence | 11.1/20 P/E 12.9× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 48.4% · 1Y — 25% evidence | |
| Exact sum: 25.8 + 17.8 + 11.1 + 12.2 = 66.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 57Exato Technologies Ltd544626 | 57.9/100Thin evidence · provisional38% evidence | BREAKING OUT | 21.1/35 Revenue — · PAT — · OPM change 3.4 pp 45% evidence | 17.5/25 ROCE 26.8% · OPM 18% 76% evidence | 9.3/20 P/E 38.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 5 weeks ahead 0% evidence |
| Exact sum: 21.1 + 17.5 + 9.3 + 10 = 57.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 58Unified Data- Tech Solutions LtdUNIFIED | 56.2/100Thin evidence · provisional36% evidence | 16.9/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 18.8/25 ROCE 45.2% · OPM 15% 76% evidence | 10.2/20 P/E 18.6× · PEG — 15% evidence | 10.3/20 RS sector — · RS bench -1.2% · 1Y -4.3%0 of 12 weeks ahead to 2026-08-23 25% evidence | |
| Exact sum: 16.9 + 18.8 + 10.2 + 10.3 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 59Kody Technolab LtdKODYTECH | 54.4/100Thin evidence · provisional48% evidence | BREAKING OUT | 15.2/35 Revenue — · PAT — · OPM change -5 pp 19% evidence | 14.6/25 ROCE 16.8% · OPM 29% 95% evidence | 8.7/20 P/E 129× · PEG — 15% evidence | 15.9/20 RS sector 10.3% · RS bench 64.4% · 1Y 111.5%10 of 10 weeks ahead 70% evidence |
| Exact sum: 15.2 + 14.6 + 8.7 + 15.9 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 60Metalic Technoforge LtdMETA | 53.1/100Thin evidence · provisional27% evidence | 16.2/35 Revenue — · PAT — · OPM change -2 pp 13% evidence | 17.1/25 ROCE 36.1% · OPM 8% 76% evidence | 9.8/20 P/E 25.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -19.1%0 of 12 weeks ahead to 2026-08-23 0% evidence | |
| Exact sum: 16.2 + 17.1 + 9.8 + 10 = 53.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 61Veefin Solutions LtdVEEFIN | 47.5/100Thin evidence · provisional50% evidence | 17.7/35 Revenue — · PAT — · OPM change -5.1 pp 19% evidence | 10.7/25 ROCE 9.8% · OPM 19.7% 76% evidence | 12.1/20 P/E 27.7× · PEG — 50% evidence | 7.0/20 RS sector -7.2% · RS bench -24.9% · 1Y -33.9%0 of 12 weeks ahead to 2026-08-23 70% evidence | |
| Exact sum: 17.7 + 10.7 + 12.1 + 7 = 47.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 62Trident Techlabs LtdTECHLABS | 45.9/100Thin evidence · provisional40% evidence | 16.0/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 16.2/25 ROCE 26.7% · OPM 27% 71% evidence | 10.6/20 P/E 14.9× · PEG — 15% evidence | 3.1/20 RS sector -50.2% · RS bench -56.5% · 1Y -69.4%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 16 + 16.2 + 10.6 + 3.1 = 45.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 63ERP Soft Systems Ltd530909 | 44.4/100Thin evidence · provisional41% evidence | 19.9/35 Revenue 19.1% · PAT 100% · OPM change -1.1 pp 53% evidence | 8.0/25 ROCE 1.6% · OPM 1.7% 57% evidence | 8.9/20 P/E 74.9× · PEG — 15% evidence | 7.6/20 RS sector — · RS bench -47.6% · 1Y -56.2%0 of 12 weeks ahead to 2026-03-29 25% evidence | |
| Exact sum: 19.9 + 8 + 8.9 + 7.6 = 44.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 64IDream Film Infrastructure Company Ltd504375 | 38.3/100Thin evidence · provisional35% evidence | TURNING | 12.9/35 Revenue — · PAT 100% · OPM change — 33% evidence | 3.1/25 ROCE -9.2% · OPM -25.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.3/20 RS sector — · RS bench 71.8% · 1Y —8 of 8 weeks ahead 25% evidence |
| Exact sum: 12.9 + 3.1 + 10 + 12.3 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Danlaw Technologies India Ltd's share price today?
Danlaw Technologies India Ltd trades at ₹1,626. The company is valued at ₹792 Cr. The stock sits at 83% of its 52-week range of ₹746–₹1,805, +54.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 14 weeks in. — as of 18 September 2026.
What were Danlaw Technologies India Ltd's latest quarterly results?
Danlaw Technologies India Ltd reported revenue of ₹73.7 Cr and net profit of ₹5.9 Cr for the Jun 26 quarter. Revenue rose 34.6% and profit rose 70.9% year on year. Earnings per share were ₹12.17. The operating margin was 13.4%, 0.8 pp higher than a year earlier. — as of 18 September 2026.
What is Danlaw Technologies India Ltd's revenue?
Danlaw Technologies India Ltd reported revenue of ₹73.7 Cr in the Jun 26 quarter, +34.6% year on year. For the full FY26 fiscal year, revenue was ₹262 Cr (+20.2%). Over the last 10 years revenue compounded at 37.3% a year. — as of 18 September 2026.
What is Danlaw Technologies India Ltd's profit?
Danlaw Technologies India Ltd earned ₹5.9 Cr of net profit in the Jun 26 quarter, +70.9% year on year — the 4th straight quarter of growth. Full-year FY26 profit was ₹23.0 Cr. The operating margin ran 13.4% in the latest quarter. — as of 18 September 2026.
What is Danlaw Technologies India Ltd's market cap?
Danlaw Technologies India Ltd's market capitalisation is ₹792 Cr at a share price of ₹1,626. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 18 September 2026.
What is Danlaw Technologies India Ltd's P/E ratio?
Danlaw Technologies India Ltd trades at a P/E of 31.1×, at the 49th percentile of its own 10-year range, against a long-run median of 32.0×. This is a comparison with the stock's own history, not a value call — as of 18 September 2026.
Does Danlaw Technologies India Ltd pay a dividend?
No — Danlaw Technologies India Ltd has recorded a dividend payout of 0% of profit in each of its last 16 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 18 September 2026.
Is Danlaw Technologies India Ltd overvalued?
On its own history, Danlaw Technologies India Ltd looks mid-range: its P/E of 31.1× sits at the 49th percentile of its 10-year range (long-run median 32.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 18 September 2026.
Is Danlaw Technologies India Ltd growing?
Yes — Danlaw Technologies India Ltd is growing: latest-quarter revenue +34.6% year on year, profit +70.9%, and the margin +0.8 pp at 13.4%. The 10-year compound rates are 37.3% (revenue) and 27.7% (profit). The earnings engine currently reads: improving — as of 18 September 2026.
How is Danlaw Technologies India Ltd performing?
Danlaw Technologies India Ltd is in a confirmed uptrend, 14 weeks in. Its latest quarter's revenue rose 34.6% and profit rose 70.9% year on year. This describes what the data did, not a rating. — as of 18 September 2026.
What stage is Danlaw Technologies India Ltd in?
Turning around — profit growth swung from −14.2% at the trough to +34.5%, a 4-quarter improving streak, ROCE lifting at 28.0%. The read comes from the last 12 quarters of growth (revenue growth +24.1% latest, profit growth +34.5% latest, eps growth +34.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 18 September 2026.
Is Danlaw Technologies India Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 14 of stage 2), trading +54.7% versus its 200-day average and at 83% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 18 September 2026.
Will Danlaw Technologies India Ltd's share price go up?
This page publishes no price forecast for Danlaw Technologies India Ltd. What it measures instead: the share price is ₹1,626, the price is in a confirmed uptrend 14 weeks in. Its P/E of 31.1× sits at the 49th percentile of its own 10-year range. — as of 18 September 2026.
Who owns Danlaw Technologies India Ltd?
Promoters hold 61.9% of Danlaw Technologies India Ltd, foreign institutions 0.0%, domestic institutions 0.0% and the public 37.2% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 18 September 2026.
Does Danlaw Technologies India Ltd have too much debt?
No — Danlaw Technologies India Ltd's debt-to-equity is 0.30, and operating profit covers the interest bill 20×. FY26 borrowings were ₹30.0 Cr against equity of ₹100 Cr. The returns on this page are earned, not borrowed — as of 18 September 2026.
What is Danlaw Technologies India Ltd's capex?
Danlaw Technologies India Ltd spent ₹30.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹12.0 Cr, with ₹8.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 18 September 2026.
What is Danlaw Technologies India Ltd's cash flow?
Danlaw Technologies India Ltd generated ₹21.0 Cr of operating cash flow in FY26 and ₹9.0 Cr of free cash flow after ₹12.0 Cr of capital spending. Reported profit that year was ₹23.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 18 September 2026.
Is Danlaw Technologies India Ltd's profit real cash?
Yes — over the last 3 fiscal years, 86% of Danlaw Technologies India Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹21.0 Cr against reported profit of ₹23.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 18 September 2026.
Where is Danlaw Technologies India Ltd in its business cycle?
Danlaw Technologies India Ltd's FY26 operating margin was 15.0%, against a 16-year band of −21.0%–18.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 13.4%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 18 September 2026.
What could break the Danlaw Technologies India Ltd story?
Biggest watch item: the price is already 14 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 18 September 2026.
Is Danlaw Technologies India Ltd a stock worth studying right now?
This is not investment advice. The machine read: Danlaw Technologies India Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 18 September 2026.
Not SEBI Registered !! Not Investment advice !!